Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial

被引:7
作者
Qi, Yuwen [1 ,2 ,3 ]
Zhang, Yaxing [1 ,2 ,3 ]
Shi, Yuying [1 ,2 ,3 ]
Yao, Shijie [1 ,2 ,3 ]
Dai, Mengyuan [1 ,2 ,3 ]
Cai, Hongbing [1 ,2 ,3 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
[2] Hubei Key Lab Tumor Biol Behav, Wuhan, Peoples R China
[3] Hubei Canc Clin Study Ctr, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
HIPEC; HRR; HRD; EOC; recurrent ovarian cancer; HOMOLOGOUS RECOMBINATION; ONCOLOGY-GROUP; PACLITAXEL; CISPLATIN; SURVIVAL; MORTALITY; CARCINOMA;
D O I
10.1177/15330338221104565
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Epithelial ovarian cancer (EOC) remains the leading cause of gynecologic cancer death worldwide due to the high recurrence rate. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an alternative modality for platinum-sensitive recurrent EOC. The latest studies demonstrate homologous recombination-related (HRR) mutation status increases the sensitivity to platinum-based chemotherapy drugs in EOC. However, the molecular analysis of recurrent EOC patient benefits from HIPEC is unknown. Thus, we aimed to evaluate the efficacy and safety of CRS combined with HIPEC for platinum-sensitive in recurrent EOC with HRR mutation. Methods: This is a phase III randomized controlled clinical trial in patients with platinum-sensitive recurrent EOC. Participants were divided into 2 groups based on the HRR mutation status and randomized to receive CRS + HIPEC. The patients then received periodic chemotherapy and follow-up. Results: The primary objective of this study was to evaluate the effect of CRS + HIPEC compared to CRS alone in patients with a platinum-sensitive recurrent EOC stratified for HRD status. We hypothesize that the addition of HIPEC to CRS improves the progression-free survival (PFS) of platinum-sensitive recurrent EOC patients with HRR mutation compared with patients without HRR mutation. Conclusion: Recurrent EOC has a poor prognosis due to implantation and metastasis in the abdominal cavity. Intraperitoneal chemotherapy reduced seeding by removing free tumor cells. HIPEC utilizes physical and biological properties to significantly increase the clearance rate of tumors. Van Driel WJ et al proposed that HIPEC using platinum-based chemotherapy improves the survival of patients with ovarian cancer. HRR mutation, as a common pathogenic mutation in ovarian cancer, has a predictive effect on the platinum sensitivity of ovarian cancer patients. Whether lobaplatin-based HIPEC will play a greater role in ovarian cancer patients with HRR mutations is currently unknown.
引用
收藏
页数:8
相关论文
共 33 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]   Platinum Compounds: A Hope for Future Cancer Chemotherapy [J].
Ali, Imran ;
Wani, Waseem A. ;
Saleem, Kishwar ;
Haque, Ashanul .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (02) :296-306
[3]  
[Anonymous], 2017, Obstet Gynecol, V130, pe110, DOI 10.1097/AOG.0000000000002296
[4]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[5]   Sociodemographic Disparities in Advanced Ovarian Cancer Survival and Adherence to Treatment Guidelines [J].
Bristow, Robert E. ;
Chang, Jenny ;
Ziogas, Argyrios ;
Campos, Belinda ;
Chavez, Leo R. ;
Anton-Culver, Hoda .
OBSTETRICS AND GYNECOLOGY, 2015, 125 (04) :833-842
[6]   Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay [J].
Bristow, Robert E. ;
Smith, Alan ;
Zhang, Zhen ;
Chan, Daniel W. ;
Crutcher, Gillian ;
Fung, Eric T. ;
Munroe, Donald G. .
GYNECOLOGIC ONCOLOGY, 2013, 128 (02) :252-259
[7]   European cancer mortality predictions for the year 2020 with a focus on prostate cancer [J].
Carioli, G. ;
Bertuccio, P. ;
Boffetta, P. ;
Levi, F. ;
La Vecchia, C. ;
Negri, E. ;
Malvezzi, M. .
ANNALS OF ONCOLOGY, 2020, 31 (05) :650-658
[8]   Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: Prospective study of 81 patients [J].
Cotte, Eddy ;
Glehen, Olivier ;
Mohamed, Faheez ;
Lamy, Franck ;
Falandry, Claire ;
Golfier, Francois ;
Gilly, Francois Noel .
WORLD JOURNAL OF SURGERY, 2007, 31 (09) :1813-1821
[9]   State of the Science: The role of HIPEC in the treatment of ovarian cancer [J].
Dellinger, Thanh H. ;
Han, Ernest S. .
GYNECOLOGIC ONCOLOGY, 2021, 160 (02) :364-368
[10]   Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case-control study on survival in patients with two year follow-up [J].
Fagotti, Anna ;
Costantini, Barbara ;
Petrillo, Marco ;
Vizzielli, Giuseppe ;
Fanfani, Francesco ;
Margariti, Pasquale Alessandro ;
Turco, Luigi Carlo ;
Piovano, Elisa ;
Scambia, Giovanni .
GYNECOLOGIC ONCOLOGY, 2012, 127 (03) :502-505